Improved asthma outcomes with dupilumab plus medium-dose inhaled corticosteroids vs placebo plus high-dose inhaled corticosteroids.

Ann Allergy Asthma ImmunolMay 23, 2026 (epub)
Clinical ResearchAllergy & Immunology

William W Busse, Mario Castro, Njira L Lugogo et al.

✦ AI-curated · Sources linked

In 30 seconds

This phase III randomized controlled trial evaluated the effects of adding dupilumab to medium-dose inhaled corticosteroids (ICS) versus high-dose ICS alone in patients with uncontrolled moderate-to-severe asthma. The study found that dupilumab plus medium-dose ICS reduced severe exacerbations by 70% compared to placebo plus high-dose ICS, indicating significant clinical benefits.

Key findings

  • Dupilumab plus medium-dose ICS reduced exacerbations by 70% vs placebo plus high-dose ICS (P < .0001).
  • At week 52, dupilumab improved prebronchodilator forced expiratory volume in 1 second by 0.22 L (P < .0001).
  • The odds ratio for achieving asthma control was 2.26 for dupilumab plus medium-dose ICS vs placebo plus high-dose ICS (P < .0001).

Why it matters

These findings suggest that adding dupilumab to medium-dose ICS may provide better control of asthma symptoms and reduce exacerbations compared to escalating to high-dose ICS, which could influence treatment strategies for patients with uncontrolled asthma.

Source

PubMed · PMID 42178021

Published in Ann Allergy Asthma Immunol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Allergy & Immunology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.